<div id="readability-page-1"><p>09:13 AM EST, 01/02/2026 (MT Newswires) -- Conduit Pharmaceuticals (CDT) said Friday that it has engaged NJS Foresight Bio-Advisor to identify, source, and support out-licensing deals for in its patent portfolio.</p><p>The hiring is meant to expand CDT's commercial reach and speed up potential licensing and royalty deals for its cocrystals and salts, which are meant to improve the solubility, bioavailability and alternative delivery modes of medicines, the company said.</p> <p>MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.</p></div>

<p>2026 年 1 月 2 日東部時間上午 9:13（MT Newswires）-- Conduit Pharmaceuticals（CDT）週五表示，已聘請 NJS Foresight Bio-Advisor 來識別、獲取並支持其專利組合的外部授權交易。該聘用旨在擴大 CDT 的商業覆蓋範圍，並加快其共晶體和鹽類的潛在授權和版税交易，這些產品旨在改善藥物的溶解度、生物利用度和替代給藥方式，公司表示。MT Newswires 不提供投資建議。未經授權的複製是嚴格禁止的</p>

導管制藥公司聘請 NJS Foresight 生物顧問以拓展交易